List view / Grid view
Antibody therapy has been a critical part of the COVID-19 research campaign to treat severe cases. Unfortunately, despite many promising candidates, scientists have yet to find one that passes clinical trials. This article by Drug Target Review’s Ria Kakkad highlights some of the most recent developments in the search for COVID-19…
Scientists have discovered antibodies that are effective against many different COVID-19 variants.
The monoclonal antibody 19A11 binds E-cadherin, a protein that helps cells stick together, especially in epithelial layers that line the skin, the gut and other organs.
A new study has shown that nanobodies derived from llamas could have the potential to destroy human cytomegalovirus.
A T-cell bispecific antibody shows potent anti-tumour activity in preclinical models of epidermal growth factor receptor variant III (EGFRvIII) mutant glioblastoma.
Scientists have found antibodies that summon virus-engulfing white blood cells may play an important role in protecting infants from cytomegalovirus.
The scientists found that the neutralising monoclonal antibody protected against SARS-CoV-2 infections in animal experiments.
The researchers found predictive protein patterns and links of maternal autoantibody–related autism spectrum disorder in the blood of expecting mothers.
A new computer-based approach could help clinicians select the best combinations of broadly neutralising antibodies to treat HIV based on the virus’ genetics, while minimising the risk of the virus escaping treatment.
Researchers have found that a broadly neutralising antibody displays strong antiviral activities against Omicron BA.1, BA1.1 and BA.2.
Researchers in the US have found that antibodies to the SARS-CoV-2 Spike protein can be produced in hen eggs.
Researchers for the first time have captured images of an autoantibody bound to a nerve cell surface receptor, revealing the physical mechanism behind a neurological autoimmune disease.
The findings have enabled researchers to design antibodies to activate important receptors on immune cells and deliver more powerful anti-cancer effects.
Researchers have found that a combination therapy that incorporates a plant virus with an immune cell-activating antibody clears colon cancer in mice.
Dr Erik Vernet, Director of Antibody Technology at Novo Nordisk, discusses antibody discovery and development workflows, including the role of informatics processes, in this Q&A.
